Novavax, Inc. (NASDAQ:NVAX) has received an average recommendation of “Hold” from the fourteen ratings firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $5.64.

Several analysts recently commented on the company. Ladenburg Thalmann Financial Services raised Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price target on the stock in a research note on Wednesday. BidaskClub downgraded Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Chardan Capital reiterated a “neutral” rating and issued a $1.50 price objective on shares of Novavax in a research report on Thursday, July 27th. Zacks Investment Research downgraded Novavax from a “buy” rating to a “hold” rating in a research report on Wednesday, July 26th. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $1.50 price objective on shares of Novavax in a research report on Wednesday, July 26th.

WARNING: “Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of “Hold” from Analysts” was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/13/novavax-inc-nasdaqnvax-receives-average-rating-of-hold-from-analysts-updated.html.

Novavax (NASDAQ:NVAX) traded up 1.8673% during midday trading on Friday, hitting $0.9983. The company had a trading volume of 3,688,982 shares. The company’s market cap is $289.41 million. The company’s 50 day moving average is $1.15 and its 200-day moving average is $1.15. Novavax has a one year low of $0.73 and a one year high of $8.49.

Get Novavax Inc. alerts:

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). The business had revenue of $6.70 million for the quarter, compared to analyst estimates of $6.15 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. Novavax’s quarterly revenue was up 168.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.29) EPS. On average, equities analysts predict that Novavax will post ($0.62) EPS for the current year.

Several large investors have recently added to or reduced their stakes in the company. Northern Trust Corp increased its stake in Novavax by 2.8% in the second quarter. Northern Trust Corp now owns 3,376,714 shares of the biopharmaceutical company’s stock worth $3,883,000 after buying an additional 92,854 shares during the last quarter. GSA Capital Partners LLP increased its stake in Novavax by 38.7% in the second quarter. GSA Capital Partners LLP now owns 1,690,153 shares of the biopharmaceutical company’s stock worth $1,944,000 after buying an additional 471,347 shares during the last quarter. Profund Advisors LLC increased its stake in Novavax by 0.4% in the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 455 shares during the last quarter. Nationwide Fund Advisors increased its stake in Novavax by 555.1% in the second quarter. Nationwide Fund Advisors now owns 1,024,020 shares of the biopharmaceutical company’s stock worth $1,178,000 after buying an additional 867,700 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in Novavax by 3.7% in the second quarter. TIAA CREF Investment Management LLC now owns 892,939 shares of the biopharmaceutical company’s stock worth $1,027,000 after buying an additional 32,092 shares during the last quarter. Institutional investors own 50.16% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.